Business
ANGLE plc:Prostate cancer ARV7 treatment biomarker
ANGLE plc:Prostate cancer ARV7 treatment biomarker.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 1632B Angle PLC 08 January 2018 \n\n\n\n\n\nFor immediate release\n\n\n 8 January 2018\n\n\n\n\n \nANGLE plc (\"the Company\")\n \nRESEARCH DEMONSTRATES USE OF PARSORTIXTM LIQUID BIOPSY TO DETECT ARV7 IN PROSTATE CANCER AS A TREATMENT SELECTION BIOMARKER\n \nParsortix-based ARV7 test may provide a wider understanding of ARV7 than other techniques with the potential for improved patient outcomes\n \nIndependent research estimates that an ARV7 test could save, on average, at least $5,000 per patient tested \n \nANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce that the University Medical Centre Hamburg-Eppendorf (UKE) together with the Medical University of Graz (Graz) and the Science for Life Laboratory, Stockholm University (SciLifeLab) have published results of work demonstrating that ANGLE's ParsortixTM system can be used to measure the expression of ARV7 (androgen receptor splice variant 7) transcripts in later stage prostate cancer patients. \n \nThe research has been published in Clinical Chemistry. A copy of the publication is available on ANGLE's website here https://angleplc.com/library/publications/.\n \nMeasurement of the expression of ARV7 on circulating tumor cells (CTCs) obtained from a blood test1 has previously been studied and found to correlate with patient response to novel hormone therapy (NHT) drugs (Enzalutamide and Abiraterone). Where ARV7 is positively expressed, patients are unlikely to respond to NHT and benefit from moving directly to taxane-based chemotherapies. Where ARV7 is not expressed, patients do better when receiving NHT first and only moving to chemotherapy subsequently. \n \nResearchers believe that an ARV7 test utilising the Parsortix system for CTC enrichment could provide key advantages over other approaches. These include: \n \n· the ability to analyse mesenchymal CTCs, so called CK (cytokeratin) negative cells, which are not captured by other CTC systems. In their research, UKE, Graz and SciLifeLab found a population of CK negative ARV7 positive cells that would not have been detected with the other label-dependent enrichment methods tested.\n \n· the ability to analyse th...